Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction.

Autor: Chiorescu RM; Department of Internal Medicine, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; Department of Internal Medicine, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania., Lazar RD; Nicolae Stăncioiu Heart Institute, 400001 Cluj-Napoca, Romania., Ruda A; Nicolae Stăncioiu Heart Institute, 400001 Cluj-Napoca, Romania., Buda AP; Nicolae Stăncioiu Heart Institute, 400001 Cluj-Napoca, Romania., Chiorescu S; Department of Surgery, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania., Mocan M; Department of Internal Medicine, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; Department of Internal Medicine, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania., Blendea D; Nicolae Stăncioiu Heart Institute, 400001 Cluj-Napoca, Romania.; Department of Cardiology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400437 Cluj-Napoca, Romania.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 28; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 28.
DOI: 10.3390/ijms25010440
Abstrakt: Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje